Skip to main content

Table 2 Clinicopathologic Characteristics of Histopathology Confirmed Treated Breast Cancer Cases.

From: Invasive breast Cancer treatment in Tanzania: landscape assessment to prepare for implementation of standardized treatment guidelines

Histopathology Confirmed Cases (n = 113)

Clinicopathologic Characteristic

Number (%)

Histopathology Method (n = 113)

 Core Biopsy

16 (14%)

 Surgical Sample

97 (86%)

Histopathology Report Time (n = 107)a

 Median (range, days)

36 (1–202)

  < 1 month

39 (36%)

  > 1 month

68 (64%)

Treatment Staging: Chest (n = 113)

 Chest X-Ray

10 (9%)

 Chest CTb

29 (26%)

 None

74 (65%)

Treatment Staging: Abdomen (n = 113)

 Abdominal ultrasound

48 (42%)

 Abdominal CT scanc

27 (24%)

 None

38 (34%)

Nodal Status (n = 113)

 Positive

38 (34%)

 Negative

10 (9%)

 Not reported

65 (57%)

Tumor Size (n = 113)

  < 2 cm

3 (3%)

 2–5 cm

27 (24%)

  > 5 cm

30 (26%)

 Not reported

53 (47%)

Tumor Grade (n = 113)

 Grade I

3 (3%)

 Grade II

34 (30%)

 Grade III

39 (34%)

 Not reported

37 (33%)

Receptor Status (n = 113)

 Hormone Receptor Tested

10 (9%)

  ER/PR negative

4 (40%)

  ER/PR positive

5 (50%)

  ER positive/PR negative

1 (10%)

 Hormone Receptor Not tested

103 (91%)

 HER2 Receptor Tested

7 (6%)

  Positive

3 (43%)

  Negative

4 (57%)

HER2 Receptor Not tested

106 (94%)

  1. a Six cases without reported histopathology report turnaround time, b Computed tomography includes those who received both X-Ray and CT, c Includes those who received both ultrasound and CT
  2. CT: Computed Tomography; ER: Estrogen Receptor; PR: Progesterone Receptor; HER2: Human Epidermal Growth Factor Receptor 2